Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42752   clinical trials with a EudraCT protocol, of which   7042   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-001219-22
    Sponsor's Protocol Code Number:SGNTV-002
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2019-09-04
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2019-001219-22
    A.3Full title of the trial
    Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen
    Estudio Abierto de Fase II de Tisotumab Vedotina para Pacientes con Cáncer Ovárico Resistente al Platino, con un Periodo de Preinclusión de Seguridad bajo un Régimen de Dosis Densas
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen
    Estudio Abierto de Fase II de Tisotumab Vedotina para Pacientes con Cáncer Ovárico Resistente al Platino, con un Periodo de Preinclusión de Seguridad bajo un Régimen de Dosis Densas
    A.3.2Name or abbreviated title of the trial where available
    innovaTV 208
    innovaTV 208
    A.4.1Sponsor's protocol code numberSGNTV-002
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorSeattle Genetics, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGenmab A/S
    B.4.2CountryDenmark
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationSeattle Genetics, Inc.
    B.5.2Functional name of contact pointSeagen Clinical Trial Information
    B.5.3 Address:
    B.5.3.1Street Address21823 30th Drive
    B.5.3.2Town/ citySeattle, Bothell, WA
    B.5.3.3Post code98021
    B.5.3.4CountryUnited States
    B.5.4Telephone number+18663337436
    B.5.6E-mailclinicaltrials@seagen.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTisotumab vedotin
    D.3.2Product code HuMax-TF-ADC
    D.3.4Pharmaceutical form Powder for concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTISOTUMAB VEDOTIN
    D.3.9.1CAS number 1418628-81-5
    D.3.9.3Other descriptive nameHuMax-TF-ADC
    D.3.9.4EV Substance CodeSUB192227
    D.3.10 Strength
    D.3.10.1Concentration unit mg/kg milligram(s)/kilogram
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number90
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeAntibody Drug Conjugate (ADC)
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTisotumab vedotin
    D.3.2Product code HuMax-TF-ADC
    D.3.4Pharmaceutical form Powder for concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTISOTUMAB VEDOTIN
    D.3.9.1CAS number 1418628-81-5
    D.3.9.3Other descriptive nameHuMax-TF-ADC
    D.3.9.4EV Substance CodeSUB192227
    D.3.10 Strength
    D.3.10.1Concentration unit mg/kg milligram(s)/kilogram
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeAntibody Drug Conjugate (ADC)
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (hereafter collectively referred to as platinum-resistant ovarian cancer and abbreviated as PROC)
    Pacientes con cáncer ovárico epitelial, cáncer peritoneal primario o cáncer de trompas de Falopio (en adelante denominados en conjunto como cáncer ovárico resistente al platino y abreviado como CORP)
    E.1.1.1Medical condition in easily understood language
    Cancer of the ovary
    Cáncer de Ovario
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10033128
    E.1.2Term Ovarian cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10016180
    E.1.2Term Fallopian tube cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10080244
    E.1.2Term Peritoneal cancer index
    E.1.2System Organ Class 10022891 - Investigations
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    (Safety run-in) Evaluate safety and tolerability of a dose-dense regimen of tisotumab vedotin
    (Phase 2) Evaluate antitumor activity of tisotumab vedotin
    (Periodo de preinclusión de seguridad) Evaluar la seguridad y la tolerabilidad de una pauta de dosis densas de tisotumab vedotina
    (Fase 2) Evaluar la actividad antitumoral de tisotumab vedotina
    E.2.2Secondary objectives of the trial
    Evaluate the safety and tolerability of tisotumab vedotin
    Evaluate preliminary antitumor activity of tisotumab vedotin
    Evaluate antitumor activity of tisotumab vedotin
    Evaluate durability of response in patients who respond to tisotumab vedotin
    Evaluate stability and control of disease
    Evaluate the timing of responses
    Evaluate progression-free survival (PFS) of patients treated with tisotumab vedotin
    Evaluate survival of patients treated with tisotumab vedotin
    Assess pharmacokinetics of tisotumab vedotin
    Assess immunogenicity of tisotumab vedotin
    Evaluar la seguridad y la tolerabilidad de tisotumab vedotina
    Evaluar la actividad antitumoral preliminar de tisotumab vedotina
    Evaluar la actividad antitumoral de tisotumab vedotina
    Evaluar la durabilidad de la respuesta en pacientes que responden a tisotumab vedotina
    Evaluar la estabilidad y el control de la enfermedad
    Evaluar el momento de presentación de las respuestas
    Evaluar la supervivencia sin progresión (SSP) en pacientes tratadas con tisotumab vedotina
    Evaluar la supervivencia en pacientes tratadas con tisotumab vedotina
    Evaluar la farmacocinética de tisotumab vedotina
    Evaluar la inmunogenicidad de tisotumab vedotina
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Histologic documentation of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (excluding carcinosarcoma, mucinous, and low grade serous histologies), hereafter referred to as “ovarian cancer”.
    2. Safety run-in patients only: Platinum-resistant ovarian cancer (PROC), which is defined as having progressed or relapsed within 6 months after previous platinum-containing chemotherapy and for which single agent chemotherapy is appropriate. Progression or relapse must be documented radiographically using RECIST v1.1 criteria. The patient may have received up to 5 prior systemic treatment regimens for ovarian cancer.
    a. Subjects may or may not have received bevacizumab for treatment of ovarian cancer.
    3. Phase 2 patients only: PROC. The patient must have received at most 1 prior cytotoxic chemotherapy regimen in the PROC setting. Patients eligible to receive a PARP inhibitor may have received such therapy; PARP inhibitors are not considered cytotoxic chemotherapy regimens for the purposes of this study.
    a. If eligible, patients must have received previous treatment with a bevacizumab-containing regimen for ovarian cancer. Prior bevacizumab may have been given at any line of treatment.
    4. Measurable disease according to RECIST v1.1 as assessed by the investigator, defined as:
    a. A minimum of one non-nodal lesion ≥10 mm in the longest diameter from a non-irradiated area. If target lesion(s) are located within previously irradiated area only, the patient can be enrolled only if there has been demonstrated progression in the “in field” lesion and upon approval of the sponsor’s medical monitor.
    OR
    b. Lymph node lesion ≥15 mm in the shortest diameter from a non-irradiated area.
    5. Age 18 years or older.
    6. An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 (see Appendix E for conversion of performance status using Karnofsky and Lansky scales, if applicable).
    7. The following baseline laboratory data:
    ● Absolute neutrophil count (ANC) ≥1500/μL assessed at least 2 weeks after growth factor support, if applicable.
    ● Platelet count ≥100 x 109/L assessed at least 2 weeks after transfusion with blood products.
    ● Hemoglobin ≥5.6 mmol/L (9.0 g/dL) assessed at least 2 weeks after transfusion with blood products.
    ● Serum bilirubin ≤1.5 x upper limit of normal (ULN) or direct bilirubin ≤2 x ULN in patients diagnosed with Gilbert’s syndrome.
    ● Estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 using the Modification of Diet in Renal Disease (MDRD) study equation as applicable
    ● Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x ULN. (If liver tumor/metastases are present, then <5 x ULN is allowed).
    8. Acceptable coagulation status:
    ● INR ≤1.2 without anticoagulation therapy.
    ● aPTT ≤1.25 ULN.
    9. Life expectancy of at least 3 months.
    1.Documentación histológica de cáncer de ovario epitelial, cáncer peritoneal primario o cáncer de las trompas de Falopio (excepto histologías mucinosas y serosas de bajo grado y carcinosarcoma), en lo sucesivo denominado "cáncer de ovario".
    2.Solo para pacientes de preinclusión de seguridad: cáncer de ovario resistente al platino (CORP), que se define como cáncer que ha progresado o presentado una recaída en los 6 meses posteriores a la quimioterapia con platino y para el que es adecuada la quimioterapia con un solo agente. La progresión o recaída debe documentarse radiológicamente según los criterios de RECIST v1.1. La paciente puede haber recibido hasta 5 pautas de tratamiento sistémico previas para el cáncer de ovario.
    a.Las pacientes pueden o no haber recibido bevacizumab para el tratamiento del cáncer de ovario
    3.Solo pacientes de la Fase 2: CORP. La paciente debe haber recibido como mucho 1 pauta de quimioterapia citotóxica anterior para el CORP. Las pacientes aptos para recibir un inhibidor de la PARP pueden haber recibido dicha terapia; los inhibidores de la PARP no se consideran pautas de quimioterapia citotóxica a efectos de este estudio.
    a.Si son elegibles, las pacientes deben haber recibido un tratamiento previo con una pauta que contuviera bevacizumab para el cáncer de ovario. El bevacizumab anterior se puede haber administrado en cualquier línea de tratamiento
    4.Enfermedad medible conforme a RECIST v1.1 según el criterio del investigador, definida como:
    a.Mínimo de una lesión no ganglionar ≥10 mm en el diámetro más largo en un área no irradiada. Si las lesiones diana se encuentran solo en un área irradiada con anterioridad, la paciente únicamente puede inscribirse si se ha demostrado una progresión en la lesión situada en el campo de irradiación y con la aprobación del monitor médico del promotor, o
    b.Lesión del ganglio linfático ≥15 mm en el diámetro más corto en un área no irradiada
    5.Tener 18 años o más
    6.Puntuación de 0 o 1 del estado funcional según el Eastern Cooperative Oncology Group (ECOG) (véase el Apéndice E para la conversión del estado funcional utilizando las escalas de Karnofsky y Lansky, si corresponde)
    7.Los siguientes datos analíticos basales:
    ●Recuento absoluto de neutrófilos (RAN) ≥1500/μL determinado como mínimo 2 semanas después de la administración de factores de crecimiento, si procede
    ●Recuento de plaquetas ≥100 x 109/L determinado como mínimo 2 semanas después de la transfusión de hemoderivados
    ●Hemoglobina ≥5.6 mmol/L (9.0 g/dL) determinada como mínimo 2 semanas después de la transfusión de hemoderivados
    ●Bilirrubina sérica ≤1.5 x límite superior de la normalidad (LSN) o bilirrubina directa ≤2 x LSN en pacientes diagnosticadas con síndrome de Gilbert
    ●Tasa de filtración glomerular estimada (TFGe) ≥50 mL/min/1.73 m2 mediante la ecuación del estudio de Modificación de la dieta en la enfermedad renal (MDRD) según corresponda
    ●Alanina aminotransferasa (ALT) y aspartato aminotransferasa (AST) ≤2.5 × LSN. (Si hay presencia de tumor/metástasis hepáticas, se permite <5 x LSN)
    8.Estado de coagulación aceptable:
    ●RIN ≤1.2 sin tratamiento anticoagulante.
    ●TTPa ≤1.25 LSN.
    9.Esperanza de vida de al menos 3 meses
    E.4Principal exclusion criteria
    1.Primary platinum-refractory disease, defined as disease progression within 2 months of completion of first line platinum-based therapy.
    2. Patients with clinical symptoms or signs of gastrointestinal obstruction within the past 6 months or who currently require parenteral nutrition.
    3.Hematological: Known past or current coagulation defects leading to an increased risk of bleeding; diffuse alveolar hemorrhage from vasculitis; known bleeding diathesis; ongoing major bleeding; trauma with increased risk of life-threatening bleeding or history of severe head trauma or intracranial surgery within 8 weeks of trial entry.
    4. Cardiovascular: Clinically significant cardiac disease including uncontrolled hypertension (systolic BP >150 mmHg or diastolic BP >90 mmHg), unstable angina, acute myocardial infarction within 6 months prior to screening, serious cardiac arrhythmia requiring medication (not including asymptomatic atrial fibrillation with controlled ventricular rate); any medical history of congestive heart failure (Class II or higher as classified by the New York Heart Association, see Appendix H), or any medical history of decreased cardiac ejection fraction of <45%.
    5. Ophthalmological: Active ocular surface disease at baseline. An ocular evaluation is to be confirmed by an ophthalmologist at screening. Patients with any prior episode of cicatricial conjunctivitis or Stevens Johnson syndrome (as evaluated by the investigator) are ineligible. Cataract is not considered active ocular surface disease for this study.
    6.History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (e.g., 5-year overall survival ≥90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, ductal carcinoma in situ, or stage I uterine cancer.
    7.Inflammatory bowel disease including Crohn’s disease and ulcerative colitis
    8.Ongoing, acute, or chronic inflammatory skin disease.
    9.Uncontrolled tumor-related pain
    10.Inflammatory lung disease, including moderate and severe asthma and chronic obstructive pulmonary disease, requiring chronic medical therapy
    11.Grade 3 or higher pulmonary disease unrelated to underlying malignancy
    12.Patients with significant peripheral vascular disease
    13.Uncontrolled pleural or pericardial effusions
    1. Enfermedad primaria refractaria al platino, definida como progresión de la enfermedad en los 2 meses posteriores a la finalización del tratamiento de primera línea basado en platino.
    2. Pacientes con signos o síntomas clínicos de obstrucción gastrointestinal en los últimos 6 meses o que actualmente requieren nutrición parenteral.
    3. Trastornos hematológicos: antecedentes o diagnostico actual de coagulopatía que aumente el riesgo de hemorragia; hemorragia alveolar difusa por vasculitis; diátesis hemorrágica conocida; sangrado mayor en curso; traumatismo con aumento del riesgo de hemorragia potencialmente mortal o antecedentes de traumatismo craneoencefálico severo o de cirugía intracraneal en el plazo de las 8 semanas previas a la entrada en el ensayo.
    4. Trastornos cardiovasculares: cardiopatía de importancia clínica que incluye hipertensión no controlada (TA sistólica >150 mmHg o diastólica >90 mmHg), angina inestable, infarto agudo de miocardio 6 meses antes de la selección, arritmia cardíaca grave que requiere medicación (salvo fibrilación auricular asintomática con respuesta ventricular controlada); antecedentes de insuficiencia cardiaca congestiva (de clase II o superior en la clasificación de New York Heart Association, véase el Apéndice H) o antecedentes de disminución de la fracción de eyección cardíaca <45 %.
    5. Trastornos oftalmológicos: enfermedades de la superficie ocular en el período basal. El oftalmólogo deberá confirmar dicha evaluación ocular en la selección. No podrán participar en el estudio pacientes con antecedentes de conjuntivitis cicatricial o de síndrome de Stevens-Johnson (según la evaluación del investigador). En este estudio, las cataratas no se consideran enfermedad activa de la superficie ocular.
    6. Antecedentes de otra neoplasia maligna en los 3 años anteriores a la primera dosis del fármaco del estudio o signos de enfermedad residual de una neoplasia maligna diagnosticada previamente. Se exceptúan las neoplasias malignas con mínimo riesgo de metástasis o de muerte (esto es, supervivencia global a los 5 años ≥90 %), como el carcinoma in situ del cuello del útero, el carcinoma cutáneo no melanómico, el carcinoma ductal in situ o el cáncer uterino en estadio I, adecuadamente tratados.
    7. Enfermedad intestinal inflamatoria, incluidas la enfermedad de Crohn y la colitis ulcerosa
    8. Enfermedad inflamatoria de la piel, aguda o crónica, en curso.
    9. Dolor no controlado relacionado con el tumor
    10. Neumopatía inflamatoria, como asma moderada o grave y enfermedad pulmonar obstructiva crónica que precise tratamiento médico prolongado
    11. Neumopatía de grado 3 o superior no relacionada con la neoplasia maligna subyacente
    12. Pacientes con enfermedad vascular periférica significativa.
    13. Derrame pleural o pericárdico no controlado.
    E.5 End points
    E.5.1Primary end point(s)
    (Safety run-in) Evaluate safety and tolerability of a dose-dense regimen of tisotumab vedotin
    (Phase 2) Evaluate antitumor activity of tisotumab vedotin
    (Periodo de preinclusión de seguridad) Evaluar la seguridad y la tolerabilidad de una pauta de dosis densas de tisotumab vedotina
    (Fase 2) Evaluar la actividad antitumoral de tisotumab vedotina
    E.5.1.1Timepoint(s) of evaluation of this end point
    Safety and tolerability will be assessed at every visit and via phone calls as needed between visits.
    La seguridad y la tolerabilidad se evaluarán en cada visita y mediante llamadas telefónicas entre visitas, según sea necesario.
    E.5.2Secondary end point(s)
    The confirmed and unconfirmed ORR according to RECIST v1.1, CA-125 response rate, combined RECIST/CA-125 overall response rate, and the DCR will be estimated and the 95% CIs will be calculated.
    Se calculará la TRO confirmada y no confirmada según RECIST v1.1, la tasa de respuesta CA-125, la tasa de respuesta general combinada RECIST/CA-125 y la DdR, y se calculará el IC del 95 %.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Radiographic tumor assessments
    Evaluaciones radiológicas de tumores
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA21
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Denmark
    Ireland
    Italy
    Spain
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The date the patient met criteria for study discontinuation and the reason for study discontinuation will be recorded.
    Se recogerá la fecha en la que la paciente cumplió los criterios para la interrupción del estudio y el motivo para la interrupción del mismo
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 64
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 78
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male No
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state9
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 47
    F.4.2.2In the whole clinical trial 142
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    none
    ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-10-25
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-10-11
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2022-02-08
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA